Most Read Articles
Dr. Joseph Delano Fule Robles, 30 Jan 2019

Five subtypes of insomnia disorder were identified by investigators from The Netherlands, addressing an unmet need to reduce the heterogeneity of insomnia disorder.

01 Feb 2019
Children with autism spectrum disorder (ASD) or developmental delays are more likely to be overweight or obese by age 5 years, a recent study has found.
28 Jan 2019
Following a healthy diet and avoiding Western dietary patterns may improve the mental health of manufacturing employees, a recent study has shown.

Sodium benzoate augments clozapine for schizophrenia

10 Feb 2018
The second generation injection may cost up to HK$5000 per month.

Sodium benzoate appears to augment the effects of clozapine, according to a recent study, which shows that the combination therapy results in significant improvements in symptomatology in clozapine-resistant schizophrenia patients.

The randomized, double-blind, placebo-controlled trial included 60 schizophrenia patients stabilized with clozapine who were randomized to receive one of three add-on treatments: 1 g/day of sodium benzoate (n=20), 2 g/day of sodium benzoate (n=20) or placebo (n=20). Add-on treatment was administered for an additional 60 days.

Both doses of sodium benzoate yielded significantly greater changes from baseline in the Scales for the Assessment of Negative Symptoms (SANS-20) scores relative to placebo at 6 weeks (p=0.029 for 1 g; p=0.031 for 2 g).

In comparison, only the 2-g sodium benzoate treatment resulted in significant 6-week improvements in the Positive and Negative Syndrome Scale (PANSS) scores compared with placebo (p=0.006).

Scores in the quality of life scale were also significantly better in the 2-g sodium benzoate vs placebo group at 6 weeks (p=0.009). No such effect was observed with 1 g of the add-on treatment.

In terms of secondary outcomes, neither 1 g or 2 g of add-on sodium benzoate resulted in significant 6-week improvements in depression, as per the Hamilton rating scale for depression (p=0.729 and p=0.114, respectively), and endpoint improvements in cognitive function (p=0.185 and p=0.930, respectively).

Minimal extrapyramidal syndrome was reported in all three groups both at baseline and at the conclusion of the study.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 30 Jan 2019

Five subtypes of insomnia disorder were identified by investigators from The Netherlands, addressing an unmet need to reduce the heterogeneity of insomnia disorder.

01 Feb 2019
Children with autism spectrum disorder (ASD) or developmental delays are more likely to be overweight or obese by age 5 years, a recent study has found.
28 Jan 2019
Following a healthy diet and avoiding Western dietary patterns may improve the mental health of manufacturing employees, a recent study has shown.